Dicerna Pharmaceuticals Inc (DRNA)


Stock Price Forecast

Dec. 27, 2021


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Dicerna Pharmaceuticals Inc chart...

About the Company

Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to silence selectively genes that cause or contribute to disease. Using its proprietary GalXC™ and GalXC-Plus™ RNAi technologies, Dicerna is committed to developing RNAi-based therapies with the potential to treat both rare and more prevalent diseases. By silencing disease-causing genes, Dicerna's GalXC platform has the potential to address conditions that are difficult to treat with other modalities. Initially focused on disease-causing genes in the liver, Dicerna has continued to innovate and is exploring new applications of its RNAi technology with GalXC-Plus, which expands on the functionality and application of its flagship liver-based GalXC technology, and has the potential to treat diseases across multiple therapeutic areas. In addition to its own pipeline of core discovery and clinical candidates, Dicerna has established collaborative relationships with some of the world's leading pharmaceutical companies, including Novo Nordisk A/S, Roche, Eli Lilly and Company, Alexion Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH and Alnylam Pharmaceuticals, Inc. Between Dicerna and its collaborative partners, they currently have more than 20 active discovery, preclinical or clinical programs focused on rare, cardiometabolic, viral, chronic liver and complement-mediated diseases, as well as neurodegenerative diseases and pain. Dicerna's mission is to interfere - to silence genes, to fight disease, to restore health.

CEO

Douglas Fambrough

Exchange

NASDAQ

Website

www.dicerna.com

$193M

Total Revenue

302

Employees

$3B

Market Capitalization

-23.45

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $DRNA News

Dicerna Pharmaceuticals Drops on Mixed Drug-Trial Results

2y ago, source: TheStreet.com

Dicerna Pharma in the fourth quarter expects to submit to the FDA a new-drug application for a treatment for hyperoxaluria, a genetic disorder. The trial included participants with primary ...

Novo Nordisk Agrees to Buy Dicerna Pharma for $3.3 Billion

2y ago, source: TheStreet.com

The two companies have been engaged in a research collaboration since 2019 using Dicerna's ribonucleic acid interference (RNAi) therapeutics to selectively silence genes that cause or contribute ...

Stephen J Hoffman's Net Worth

29d ago, source: Benzinga.com

This is based on reported shares across multiple companies, which include Dicerna Pharmaceuticals Inc, Sirtris Pharmaceuticals, Inc., TETRAPHASE PHARMACEUTICALS INC, Aerpio Pharmaceuticals ...

Top 5 Stock Market Picks

5y ago, source: FXEmpire.com

Here are 5 top stock picks for the current market: Macerich (MAC), Dicerna Pharmaceuticals, Inc. (DRNA), Comcast (CMCSA), Steven Madden, Ltd. (SHOO) and Abeona Therapeutics Inc. (ABEO). Macerich ...

BCIP Life Sciences Associates, LP's Net Worth

15d ago, source: Benzinga.com

This is based on reported shares across multiple companies, which include Dicerna Pharmaceuticals Inc, MARINUS PHARMACEUTICALS INC, RAPID MICRO BIOSYSTEMS, INC., Arcutis Biotherapeutics ...

Alnylam Pharmaceuticals

2d ago, source: Forbes

Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new ...

Vertex Pharmaceuticals Inc VRTX

3d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Boehringer reinforces interest in NASH with new $2bn deal

2mon ago, source: GlobalData on MSN

Boehringer Ingelheim is intensifying efforts to combat non-alcoholic steatohepatitis (NASH) through a new multi-target ...

MRNS Marinus Pharmaceuticals, Inc.

15d ago, source: Seeking Alpha

Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure ...

Oramed Pharmaceuticals Inc ORMP

3d ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

Q4 2023 Cumberland Pharmaceuticals Inc Earnings Call

22d ago, source: Yahoo Finance

Todd Anthony; VP & Organizational Development; Cumberland Pharmaceuticals Inc. Operator Good afternoon, and welcome to Cumberland Pharmaceuticals 2023 financial report and company. Our call is ...

SNOA Sonoma Pharmaceuticals, Inc.

9d ago, source: Seeking Alpha

Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...